AstraZeneca: Tezepelumab Trial Didn't Meet Primary Endpoint

By Sabela Ojea

AstraZeneca PLC said Tuesday that the 48-week Phase 3 trial of the potential new medicine tezepelumab--aimed at treating severe asthma--didn't meet the primary endpoint.

The British-Swedish pharmaceutical major said the trial didn't show a "statistically significant reduction in the daily use of oral corticosteroids without loss of asthma control, with tezepelumab compared to placebo."

The initial analysis of the trial indicates that its design might have contributed to the outcome of the primary endpoint, adding that it is analyzing the data to share the results, the FTSE-100 listed company said.

"We remain confident that tezepelumab has the potential to improve care for a broad population of severe asthma patients," Mene Pangalos, executive vice president of biopharmaceuticals research and development, said.

The safety profile of the medicine in the trial was consistent with previous trials, AstraZeneca added.

Write to Sabela Ojea at [e-mail]; @sabelaojeaguix

(END) Dow Jones Newswires

December 22, 2020 02:38 ET (07:38 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.